512 related articles for article (PubMed ID: 20923244)
1. Bioequivalence of sitagliptin/metformin fixed-dose combination tablets and concomitant administration of sitagliptin and metformin in healthy adult subjects: a randomized, open-label, crossover study.
Migoya EM; Miller JL; Gutierrez M; Zheng W; Johnson-Levonas AO; Liu Q; Matthews CZ; Wagner JA; Gottesdiener KM
Clin Drug Investig; 2010; 30(12):855-66. PubMed ID: 20923244
[TBL] [Abstract][Full Text] [Related]
2. A fixed-dose combination tablet of gemigliptin and metformin sustained release has comparable pharmacodynamic, pharmacokinetic, and tolerability profiles to separate tablets in healthy subjects.
Park SI; Lee H; Oh J; Lim KS; Jang IJ; Kim JA; Jung JH; Yu KS
Drug Des Devel Ther; 2015; 9():729-36. PubMed ID: 25678778
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of a fixed-dose combination of atorvastatin and metformin extended release versus concurrent administration of individual formulations: a randomized, open-label, two-treatment, two-period, two-sequence, single-dose, crossover, bioequivalence study.
Kandhwal K; Dey S; Nazarudheen S; Arora R; Reyar S; Thudi NR; Monif T; Singh MK; Rao S
Clin Drug Investig; 2011 Dec; 31(12):853-63. PubMed ID: 21919543
[TBL] [Abstract][Full Text] [Related]
4. Bioequivalence of saxagliptin/metformin extended-release (XR) fixed-dose combination tablets and single-component saxagliptin and metformin XR tablets in healthy adult subjects.
Boulton DW; Smith CH; Li L; Huang J; Tang A; LaCreta FP
Clin Drug Investig; 2011; 31(9):619-30. PubMed ID: 21819160
[TBL] [Abstract][Full Text] [Related]
5. Investigation of bioequivalence of a new fixed-dose combination of acarbose and metformin with the corresponding loose combination as well as the drug-drug interaction potential between both drugs in healthy adult male subjects.
Kim S; Jang IJ; Shin D; Shin DS; Yoon S; Lim KS; Yu KS; Li J; Zhang H; Liu Y; Brendel E; Blode H; Wang Y
J Clin Pharm Ther; 2014 Aug; 39(4):424-31. PubMed ID: 24806030
[TBL] [Abstract][Full Text] [Related]
6. Bioequivalence of saxagliptin/metformin immediate release (IR) fixed-dose combination tablets and single-component saxagliptin and metformin IR tablets in healthy adult subjects.
Upreti VV; Keung CF; Boulton DW; Chang M; Li L; Tang A; Hsiang BC; Quamina-Edghill D; Frevert EU; Lacreta FP
Clin Drug Investig; 2013 May; 33(5):365-74. PubMed ID: 23549864
[TBL] [Abstract][Full Text] [Related]
7. Fixed-dose combination tablet of repaglinide and metformin is bioequivalent to concomitantly administered individual tablets of repaglinide and metformin : randomized, single-blind, three-period crossover study in healthy subjects.
Hoelscher D; Chu PL; Lyness W
Clin Drug Investig; 2008; 28(9):573-82. PubMed ID: 18666804
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the bioavailability and tolerability of fixed-dose combination glimepiride/metformin 2/500-mg tablets versus separate tablets: A single-dose, randomized-sequence, open-label, two-period crossover study in healthy Korean volunteers.
Gu N; Kim BH; Rhim H; Chung JY; Kim JR; Shin HS; Yoon SH; Cho JY; Shin SG; Jang IJ; Yu KS
Clin Ther; 2010 Jul; 32(7):1408-18. PubMed ID: 20678687
[TBL] [Abstract][Full Text] [Related]
9. Triple fixed-dose combination empagliflozin, linagliptin, and metformin for patients with type 2 diabetes.
Lingvay I; Beetz N; Sennewald R; Schuler-Metz A; Bertulis J; Loley C; Lang B; Lippert C; Lee J; Manning LS; Terada D
Postgrad Med; 2020 May; 132(4):337-345. PubMed ID: 32366156
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic Equivalence of the High Dose Strength Fixed-Dose Combination Tablet of Gemigliptin/Metformin Sustained Release (SR) and Individual Component Gemigliptin and Metformin XR Tablets in Healthy Subjects.
Cho YS; Lee SH; Lim HS; Bae KS
J Korean Med Sci; 2018 Oct; 33(41):e258. PubMed ID: 30288156
[TBL] [Abstract][Full Text] [Related]
11. Bioequivalence of vildagliptin/metformin fixed-dose combination tablets and a free combination of vildagliptin and metformin in healthy subjects.
He YL; Paladini S; Sabia H; Campestrini J; Zhang Y; Leon S; Ligueros-Saylan M; Jarugula V
Int J Clin Pharmacol Ther; 2008 May; 46(5):259-67. PubMed ID: 18538112
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of a fixed-dose combination of mitiglinide and metformin versus concurrent administration of individual formulations in healthy subjects: a randomized, open-label, two-treatment, two-period, two-sequence, single-dose, crossover study.
Jung JA; Kim JR; Kim SR; Kim TE; Lee SY; Ko JW; Huh W
Clin Drug Investig; 2012 Dec; 32(12):799-804. PubMed ID: 23100167
[TBL] [Abstract][Full Text] [Related]
13. Linagliptin fixed-dose combination with metformin is bioequivalent to co-administration of linagliptin and metformin as individual tablets.
Buschke S; Ring A; Friedrich C; Metzmann K; Meinicke T
Int J Clin Pharmacol Ther; 2014 Jul; 52(7):537-48. PubMed ID: 24755123
[TBL] [Abstract][Full Text] [Related]
14. Effect of food and tablet-dissolution characteristics on the bioavailability of linagliptin fixed-dose combination with metformin: evidence from two randomized trials.
Metzmann K; Schnell D; Jungnik A; Ring A; Theodor R; Hohl K; Meinicke T; Friedrich C
Int J Clin Pharmacol Ther; 2014 Jul; 52(7):549-63. PubMed ID: 24755124
[TBL] [Abstract][Full Text] [Related]
15. Lack of pharmacokinetic interaction between dapagliflozin, a novel sodium-glucose transporter 2 inhibitor, and metformin, pioglitazone, glimepiride or sitagliptin in healthy subjects.
Kasichayanula S; Liu X; Shyu WC; Zhang W; Pfister M; Griffen SC; Li T; LaCreta FP; Boulton DW
Diabetes Obes Metab; 2011 Jan; 13(1):47-54. PubMed ID: 21114603
[TBL] [Abstract][Full Text] [Related]
16. Tolerability and pharmacokinetics of metformin and the dipeptidyl peptidase-4 inhibitor sitagliptin when co-administered in patients with type 2 diabetes.
Herman GA; Bergman A; Yi B; Kipnes M;
Curr Med Res Opin; 2006 Oct; 22(10):1939-47. PubMed ID: 17022853
[TBL] [Abstract][Full Text] [Related]
17. Bioequivalence of Ertugliflozin/Metformin Fixed-Dose Combination Tablets and Coadministration of Respective Strengths of Individual Components.
Dawra VK; Liang Y; Wei H; Pelletier K; Shi H; Hickman A; Bass A; Terra SG; Zhou S; Krishna R; Sahasrabudhe V
Clin Pharmacol Drug Dev; 2020 Jan; 9(1):50-61. PubMed ID: 31207178
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and bioequivalence evaluation of gliclazide/metformin combination tablet and equivalent doses of gliclazide and metformin in healthy Korean subjects.
Cho HY; Yoon H; Lim YC; Lee YB
Int J Clin Pharmacol Ther; 2009 Dec; 47(12):770-9. PubMed ID: 19954716
[TBL] [Abstract][Full Text] [Related]
19. Fed and Fasted Single-dose Assessment of Bioequivalence of Dapagliflozin and Metformin Extended-release Fixed-dose Combination Tablets Relative to Single-component Dapagliflozin and Metformin Extended-release Tablets in Healthy Subjects.
Boulton DW; Chang M; Griffen SC; Kitaura C; Lubin S; Pollack A; LaCreta F
Clin Ther; 2016 Jan; 38(1):99-109. PubMed ID: 26682500
[TBL] [Abstract][Full Text] [Related]
20. Bioequivalence of Metformin in Ertugliflozin/Metformin Fixed-Dose Combination Tablets to Canadian-Sourced Metformin Coadministered With Ertugliflozin Under Fasted and Fed States.
Dawra VK; Pelletier K; Matschke K; Shi H; Hickman A; Zhou S; Krishna R; Sahasrabudhe V
Clin Pharmacol Drug Dev; 2021 May; 10(5):510-520. PubMed ID: 33135865
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]